| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10842770 | SHILPA | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
Aug, 2031
(7 years from now) | |
| US9763880 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
| US8940786 | SHILPA | Non-aqueous taxane nanodispersion formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
| US9308195 | SHILPA | Non-aqueous taxane formulations and methods of using the same |
Sep, 2033
(9 years from now) | |
Docetaxel is owned by Shilpa.
Docetaxel contains Docetaxel.
Docetaxel has a total of 4 drug patents out of which 0 drug patents have expired.
Docetaxel was authorised for market use on 22 December, 2015.
Docetaxel is available in injectable;injection dosage forms.
Docetaxel can be used as method of administering an ethanol-free taxane liquid nanodispersion formulation to a subject combining the formulation with an aqueous medium to provide an ethanol-free taxane diluted solution, treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy; treatment of patients with locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil; use in combination with doxorubicin and cyclophosphamide for adjuvant treatment of patients with operable node-positive breast cancer; treatment of patients with locally advanced metastatic breast cancer after failure of prior chemotherapy; use in combination with cisplatin for treatment of unresectable, locally advanced or metastatic non-small cell lung cancer without prior chemotherapy treatment; treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer in combination with prednisone; treatment of advanced gastric adenocarcinoma in combination with cisplatin and fluorouracil in patients that have not received prior chemotherapy, method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion.
The generics of Docetaxel are possible to be released after 30 September, 2033.
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 22 December, 2015
Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion; Treatment of patients with locally advanced or met...
Dosage: INJECTABLE;INJECTION
DOCETAXEL family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398785 | MERIDIAN LABS | Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use |
Mar, 2036
(12 years from now) | |
Docetaxel is owned by Meridian Labs.
Docetaxel contains Docetaxel.
Docetaxel has a total of 1 drug patent out of which 0 drug patents have expired.
Docetaxel was authorised for market use on 22 November, 2022.
Docetaxel is available in solution;intravenous dosage forms.
The generics of Docetaxel are possible to be released after 14 March, 2036.
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 22 November, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
DOCETAXEL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic